Cell therapy (TCR-T) · Kills target cells, directed at patient-specific tumor-associated antigens · developed by Immatics US
IMA202 is a preparation of autologous T-lymphocytes genetically modified with a lentiviral vector encoding a T-cell receptor that targets patient-specific tumor-associated antigens. After intravenous administration, the engineered T-cells recognize these antigens on cancer cells and induce a cytotoxic T-lymphocyte-mediated response against them. It is studied in adult solid tumors, including refractory and recurrent cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03441100 | Phase 1 | Solid Tumor, Adult | Completed | IMTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CancerRecurrent CancerRefractory CancerSolid Tumor, Adult
Updated Nov 15, 2026. Something wrong or missing? Report it on the IMTX page.
See IMTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMTX catalysts and pipeline →